A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

Part of paid clinical trials in San Antonio, Texas.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07422298
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • BMS-986278 — DRUG
    Specified dose on specified days
  • Placebo — DRUG
    Specified dose on specified days
  • Moxifloxacin — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the effect of BMS-986278 on the cardiac repolarization in healthy participants.

Key Dates

First listed
Feb 20, 2026
Start date
Feb 19, 2026
Status verified
Jul 2026
Primary completion
Jun 14, 2026
Completion
Jun 14, 2026

Study Design

Enrollment
32 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment A
  • Experimental: Treatment B
  • Placebo Comparator: Treatment C
  • Experimental: Treatment D

Primary Outcome Measure

Change from baseline Fridericia's corrected QT interval (QTcF) (ΔQTcF) [ Time Frame: Up to Day 13 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Local Institution - 0001San AntonioTexas78217-

Find similar trials in San Antonio, TX

By research site
Local Institution - 0001· San Antonio, TX

Related Studies